乙莫克舍

乙莫克舍

中文名称乙莫克舍
中文同义词乙莫克舍;R-(+)-ETOMOXIR 乙莫克舍;(R)-2-(6-(4-氯苯氧基)己基)环氧乙烷-2-羧酸乙酯;依莫克舍;化合物 T4535L;ETOMOXIR乙莫克舍
英文名称R-(+)-Etomoxir
英文同义词(R)-2-[6-(4-Chlorophenoxy)hexyl]oxirane-2-carboxylic acid ethyl ester;2-Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester, (2R)-;(2S)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylic acid ethyl ester;ethyl (2S)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate;(2R)-2-[6-(4-Chlorophenoxy)hexyl]-2-oxiranecarboxylic acid ethyl ester;2-Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester, (2R)-(R)-(+)-Etomoxir;S-(+)-ETOMOXIR;(S)-2-[6-(4-CHLOROPHENOXY)HEXYL]OXIRANECARBOXYLIC ACID, ETHYL ESTER
CAS号124083-20-1
分子式C17H23ClO4
分子量326.82
EINECS号200-258-5
相关类别试剂;Chiral Reagents;Inhibitors
Mol文件124083-20-1.mol
结构式乙莫克舍 结构式

乙莫克舍 性质

熔点32-34°C
沸点405.0±25.0 °C(Predicted)
密度1.163
储存条件Inert atmosphere,2-8°C
溶解度DMSO 中≥32.7 mg/mL;乙醇中≥109.6 mg/mL;温和加热时,水中≥48.3 mg/mL
形态粉末
颜色无色至浅黄
InChIInChI=1S/C17H23ClO4/c1-2-20-16(19)17(13-22-17)11-5-3-4-6-12-21-15-9-7-14(18)8-10-15/h7-10H,2-6,11-13H2,1H3/t17-/m1/s1
InChIKeyDZLOHEOHWICNIL-QGZVFWFLSA-N
SMILESO1C[C@]1(CCCCCCOC1=CC=C(Cl)C=C1)C(OCC)=O

乙莫克舍 用途与合成方法

Etomoxir ((R)-(+)-Etomoxir) 是肉碱棕榈酰转移酶 1a (CPT-1a) 抑制剂,通过抑制 CPT-1a 可抑制脂肪酸氧化,并抑制人、大鼠和豚鼠中棕榈酸酯的氧化。

CPT-1a

Etomoxir binds irreversibly to the catalytic site of CPT-1 inhibiting its activity, but also upregulates fatty acid oxidation enzymes. Etomoxir is developed as an inhibitor of the mitochondrial carnitine palmitoyltransferase-1 (CPT-1) located on the outer mitochondrial membrane. Etomoxir, in the liver can act as peroxisomal proliferator, increasing DNA synthesis and liver growth. Thus, etomoxir, in addition of being a CPT1 inhibitor could be considered as a PPARalpha agonist. Etomoxir is a member of the oxirane carboxylic acid carnitine palmitoyl transferase I inhibitors and has been suggested as a therapeutic agent for the treatment of heart failure. Acute Etomoxir treatment irreversibly inhibits the activity of carnitine palmitoyltransferase I. As a result, fatty acid import into the mitochondria and β-oxidation is reduced, whereas cytosolic fatty acid accumulates and glucose oxidation is elevated. Prolonged incubation (24 h) with Etomoxir produces diverse effects on the expression of several metabolic enzyme.

Etomoxir is an inhibitor of free fatty acid (FFA) oxidation-related key enzyme CPT1. P53 interacts directly with Bax, which is inhibited by Etomoxir, further confirming the direct interaction of P53 and Bax, and the involvement of FAO-mediated mitochondrial ROS generation in db/db mice. Rats are injected daily with Etomoxir, a specific CPT-I inhibitor, for 8 days at 20 mg/kg of body mass. Etomoxir-treated rats display a 44% reduced cardiac CPT-I activity. The treatment of Lewis rats for 8 days with 20 mg/kg Etomoxir does not alter blood glucose, which is in line with comparable etomoxir-feeding studies. Similarly, Etomoxir feeding does not affect general growth characteristics such as gain in body mass, nor does it affect hindlimb muscle mass. However, heart mass and liver mass are both significantly increased by 11% in Etomoxir-treated rats.

安全信息

MSDS信息

乙莫克舍 上下游产品信息

"乙莫克舍"相关产品信息
(R)-(+)-乙莫克舍钠盐 乙莫克舍
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 | 评选活动 | HS海关编码 | MSDS查询 | 化工站点

Copyright © 2016-2023 ChemicalBook 版权所有  京ICP备07040585号  京公海网安备11010802032676号  

互联网增值电信业务经营许可证:京ICP证150597号  互联网药品信息服务资格证编号(京)-非经营性-2015-0073  信息系统安全等级保护备案证明(三级)  营业执照公示

根据相关法律法规和本站规定,单位或个人购买相关危险物品应取得有效的资质、资格条件。
参考《应急管理部等多部门关于加强互联网销售危险化学品安全管理的通知 (应急〔2022〕119号)》《互联网危险物品信息发布管理规定》